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M a n u s c r i p t 
Zusanli (ST36) acupoint injection for preventing postoperative ileus: a systematic review and meta-analysis of randomized clinical trials

Introduction
Postoperative ileus (POI), is a common condition after abdominal surgery that presents with discomfort, pain, nausea, vomiting, and abdominal distension. It is a major contributory factor to extended hospitalization and increased costs. [1] [2] [3] POI is generally defined as a transient impairment of bowel motility after abdominal surgery or other injury. 1 Duration of POI varies from a few hours to several weeks. Recent studies show that, on average, patients with a diagnosis of POI stay 5 days longer in hospital after abdominal surgery than patients without POI. 4 In the US the economic consequences of POI are estimated to surpass one billion dollars each year. 5 Currently, no effective techniques are available for the management of POI. 1, 6 Usually, after abdominal surgery, current practice is to withhold oral feeding until POI resolves, 7, 8 but the evidence for this has been questioned recently. 1 Several strategies, including minimizing intestinal trauma during surgery, using midthoracic epidural anaesthesia and minimizing the need for opioids in pain management, do shorten the time of POI but it remains a major problem. 6 Pharmacological approaches including metoclopramide, erythromycin, beta blockers, laxatives, neostigmine, and naloxone, have limited clinical efficacy and safety for treating POI. [9] [10] [11] Gum chewing is associated with improved gastrointestinal function for preventing POI, but it is limited using in sleepy, drowsy, or older patients or in patients without teeth. 12 Further research is urgently needed to identify and develop new interventions for the prevention of POI.
Acupoint injection therapy emerged in 1950s in China; it originated from intramuscular injection in western medicine and was gradually integrated into traditional Chinese medicine. 13 After its initial development acupoint injection therapy is widely used in China for a variety of indications including POI, pain, vomiting, nausea and
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A c c e p t e d M a n u s c r i p t 6 retention of urine. 14 Acupoint injection is an acupoint stimulating technique in which a liquid agent is injected to prevent and/or treat disease. The agents usually used for acupoint injection include bee venom, Chinese herbal extractions, western medications, vitamins, and normal saline. 15 The commonly used acupoint in treating gastrointestinal diseases is Zusanli (ST36). 16, 17 ST36 is located on the Stomach
Meridian and its action, harmonizes qi and blood, adjusts the spleen and stomach, and improves general weakness; its traditional therapeutic properties are ideally suited to treating POI. 18 Electroacupuncture at ST36 at a specific frequency can improve gastrointestinal functional diseases. 19 Agents administrated in acupoints, through the meridians, are thought to play a synergistic effect with acupoint stimulation, and are thought to have a more sustained effect than traditional acupuncture needling or simple intra-muscular injection. 20 ST36 acupoint injections with various agents have been widely used as a preventative method for POI in China for many years but have not been part of standard of postoperative care in clinical practice due to a lack of systematic evidence demonstrating its efficacy and safety. We therefore performed a systematic review and meta-analysis of randomized clinical trials to evaluate the preventive effect of ST36 acupoint injections with various agents for POI.
Methods
Registration number
The protocol of this systematic review was registered in the PROSPERO database (http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CR D42014007443). MeSH term "postoperative"; key words: "postoperative ileus" or "POI" or "gastrointestinal function recovery" or "gastrointestinal disorder" and "ST36" or "zusanli" and "acupuncture" or "aquapuncture" or "*point injection" or "acupoint block" and "randomiz*". Clinical trials were set as a limitation for searching. We also searched relevant ongoing trials from the US equivalent Clinical Trials register (http://www.clinicaltrials.gov).
Search strategy
Inclusion/exclusion criteria
Types of studies
Randomized clinical trials (RCTs) were included. Quasi-RCTs (clinical trials allocated participants based on alternation, such as date of birth, hospital medical record number) were excluded. We excluded case series, case reports, reviews and animal studies. There was no limitation on language or type of publication.
Types of participants
Participants who underwent elective or emergent abdominal surgery without experiencing POI or any complications were included. There were no limitations on age, gender, original abdominal disease or type of surgery. We excluded postoperative patients who failed to have flatus within a prespecified duration of time.
Types of interventions
ST-36, is located 3 cun below the lower border of the patella, 1 fingers' breadth lateral A c c e p t e d M a n u s c r i p t 8 to the anterior crest of the tibia, in the tibialis anterior musle. 21 Cun is defined according to the rules of traditional acupuncture as the width of the interphalangeal joint of the patient's thumb. 22 When the needles are inserted into ST36 acupoint, patients feel deqi (a sensation of dull, aching, and spreading), 23 and then agents are slowly injected. Deqi or needling sensation is the traditional acupuncture term used to describe the supposed connection between acupuncture needles and the acupuncture meridians. 24 Agents that are injected at ST36 acupoint as part of a therapeutic approach designed to sustain and amplify the effects of simple needling. These agents included vitamins, normal saline (as a therapy), various pharmaceutical medications and herbal extracts. There was no limitation on sensation of deqi and how located the acupoint. Single or combination of the agents to be injected was included. The controls included usual care (stomach decompression, nasogastric tube, mobilization from bedrest and maintaining body fluid balance), placebo, or the same medication used in the acupoint injection given through another method (e.g. routine intramuscular injection). We excluded trials comparing ST36 acupoint injection with other type of ST36 acupoint stimulation such as manual acupuncture, electro-acupuncture, or acupoint paste, which could not manifest the holistic effect of acupoint and agents.
Types of outcome measures
The primary outcome was time to first flatus. Secondary outcomes were time to bowel sounds recovery, time to first defecation, length of hospital stay, abdominal distention, time to recovery of oral dietary intake and adverse events. Bowel sounds were recorded at four quadrants of the abdomen with a standard interval (often every 2 hrs) after ST36 acupoint injection until heard three times per minute. This suggested bowel sounds recovery. We excluded trials with missing outcome data or not available 
Assessment of risk of bias in included studies
Two authors (MW and YHG) independently assessed the methodological quality of included trials, and a consensus was reached by discussion with JPL in case of disagreement.
We assessed methodological quality of RCTs according to the risk of bias tool in the Cochrane handbook for systematic reviews of interventions. 25 The following items were assessed: random sequence generation, allocation concealment, blinding of outcome assessors, incomplete outcome data, selective reporting and other bias. The risk of bias was categorized as low, unclear, or high risk of bias.
Data analysis
We used mean difference (MD) with 95% CI for effect estimates. We applied RevMan 5.2.0 software for data analyses. Heterogeneity was assessed using the I 2 (defined as significant if I 2 >75%). We used random effects model (REM) for pooling data with significant heterogeneity. Funnel plots were generated to detect publication bias.
When the data were available, subgroup analysis was done for different injected A c c e p t e d M a n u s c r i p t 10 agents and different outcomes.
Results
Our search identified 689 citations, and 30 RCTs were eligible, as summarized in the flow chart (Fig. 1) . (needling feeling which is felt as dull, aching, and spreading).
Description of studies
The controls included usual care in 23 trials; intra-muscular injection (the same agents as given for ST36 acupoint injection) in five trials; and other medicines in two trials (oral mosapride, domperidone; castor oil via gastric tube). Comparing the same agents administrated through ST36 acupoint injection with intra-muscular injection, the controls were initiated at same time and given at same dosage as the interventions.
Most trials had two-arms, five trials had three arms, 30,31,33,36,55 and two trials had four arms 26, 29 . For trials involving multi-arms, we included the arms of usual care or intramuscular injection, and excluded arms of acupoint stimulation based on our 
Risk of bias assessment
All of the included trials were assessed to be of high risk of bias in general suggesting poor methodological quality according to the predefined quality criteria (Fig.2 ).
Although 'random allocation' was mentioned in all trials, only eight (26.67%, 8/30) trials described the methods for random sequence generation as a random number evidence of appropriate blinding of participants or study personnel performed in any of the included trials. Although no blinding of outcome assessment was performed in any trials, we considered this was probably a low risk of bias because the time to first defecation was the participants' self-reported outcome. Since the protocols of the included trials were not available, we assessed the selective outcome reporting by comparing the outcome measures described in the methods section with the actual reporting in the results. In total, two trials were assessed as high risk of bias for selective reporting. Two trials reported sample size calculation.
33, 36
Effects of interventions
Page 12 of 32 A c c e p t e d M a n u s c r i p t 12 We did subgroup analyses based on different agents injected at ST36 acupoint.
Primary outcome
Time to first flatus
All trials reported outcomes of time to first flatus. Meta-analysis showed ST36 A c c e p t e d M a n u s c r i p t 13 I 2 =95%, REM). The detailed effect estimates are presented in Table 2 . Table 2 .
2.Time to defecation
Adverse events
Of the 30 trials, 28 trials did not mention information on adverse events; two trials reported that no adverse events occurred.
44,47
Funnel plot analysis
A funnel plot analysis of 30 RCTs for the outcome of time to first flatus was performed to explore publication bias (Fig 4) . The plot was asymmetrical suggesting the existence of publication bias.
Discussion
Main findings
Our review of 30 RCTs with 2,967 participants evaluated the preventive effect of 
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